IRVINE, Calif.--(BUSINESS WIRE)--Immunis, Inc., a clinical-stage biotech developing novel secretomes for age-related diseases and immune dysfunction, has initiated non-terminal safety studies with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback